drugset

drugset / Trial / NCT00044395

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

NCT00044395 ↗

Phase 3 Completed 200 enrolled Eli Lilly and Company

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.

Timeline

Start: 2002-07
Primary completion: —
Completion: 2005-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruboxistaurin	Small molecule	—	—

Indications